Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 34 n° 349

Posts Tagged ‘sciences’

The lessons of life sciences for the British economy

Posted by fidest press agency su martedì, 26 luglio 2022

We have two covers this week. In most of the world we argue that ESG is deeply flawed. Environmental, social and governance investing is one of the hottest trends in finance. Companies are eager to tout their ESG credentials; investors who want to save the world buy ESG funds; asset managers charge higher fees for them. Yet the measure is incoherent, lumping together a dizzying array of objectives and offering no guide to trade-offs. Elon Musk is a corporate-governance nightmare, yet by popularising electric cars he helps fight climate change. Closing a coal mine is good for the environment, but awful for workers who are laid off. The measure needs to be simplified. Drop the S and the G, we argue, and shift the E from “environment” to “emissions”. If the measurement of firms’ carbon footprints were standardised, they would be easier to shrink. In Britain we argue that the next prime minister, whether it is Rishi Sunak or Liz Truss, should learn from the country’s life-sciences industry. There is no better example of Britain’s strengths, which include scientific excellence, fine universities and a healthy startup culture. British life-sciences work in an ecosystem including the National Health Service, which among other things is a cradle-to-grave source of data for drug trials. The industry’s innovations include the covid-19 vaccine that saved more lives than any other. But there is not enough growth capital, Brexit threatens scientific collaboration and the government’s aversion to investing in already-wealthy regions, or spoiling the view from any voter’s front window, makes it hard to build the right infrastructure. The candidates who claim Margaret Thatcher’s mantle today should remember the steel she displayed to drag Britain out of a previous economic rut. If you subscribe to The Economist, we have a new weekly newsletter launching this Saturday just for you. The Bottom Line will give you a panoramic sweep of the fast-changing world of tech and business. Each edition will contain exclusive commentary from our global editors, from Silicon Valley to Shanghai. I encourage you to sign up here. Zanny Minton Beddoes Editor-in-chief The Economist

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Sheppard Mullin Expands Life Sciences Team in Del Mar

Posted by fidest press agency su mercoledì, 8 gennaio 2020

Sheppard, Mullin, Richter & Hampton LLP is pleased to announce that Scott E. Oross has joined the firm’s Del Mar office as a partner in the firm’s Corporate practice group and as a member of the Life Sciences and FDA industry team. Oross was most recently a partner at Paul Hastings. The addition of Oross follows that of partner Jing Liu and associate Paul Chang who joined the Life Sciences and FDA industry team in Del Mar last April. Oross focuses his practice on emerging company and venture capital work, representing companies and investors in a number of different industries, with a primary focus on life sciences. His work includes a wide range of corporate transactions, including public and private offerings of equity and debt securities, mergers and acquisitions and strategic collaborations. He also regularly advises boards of directors and management on a variety of strategic and corporate governance issues. He received his B.A. from the University of Notre Dame, summa cum laude, and his J.D. from Vanderbilt Law School, where he was a John W. Wade Scholar. Oross is currently a board member of Connect w/ San Diego Venture Group, the leading organization in San Diego that supports local entrepreneurs.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Life Sciences to create new opportunities for regenerative tissue manufacturing

Posted by fidest press agency su giovedì, 12 dicembre 2019

GE Healthcare Life Sciences and Advanced Solutions Life Sciences (ASLS) will enter into a strategic R&D and distribution partnership that sets out to personalize tissue regeneration. The integration of IN Cell Analyzer and BioAssemblyBot® systems technologies will embed cellular-level assessments into the 3D-bioprinting workflow used to create human tissue models.
Bioprinted tissues are small in size and die quickly, due to an inability to engineer small blood vessels – the body’s supply network. ASLS’ patented Angiomics® technology enables bioprinted microvessels to self-assemble into functional capillary beds, which deliver nutrients, oxygen, and hormones to the 3D tissue model and remove waste. This partnership would allow life scientists and tissue engineers to quickly design, build and image living, vascularized 3D tissues in a single, agile process.Emmanuel Abate, General Manager of Genomics & Cellular Research, GE Healthcare Life Sciences, says: “Printing multi-material 3D objects inside of microwell plates allows scientists to efficiently move away from traditional 2D monocultures on plastic, to 3D discovery and cytotoxicity models that more accurately reflect native biology and disease. By combining this flexibility and precision of the BioAssemblyBot® with the image quality and speed of the IN Cell Analyzer 6500 HS confocal screening platform, the prospect of automating high content screening in 3D models can become a reality.” Currently, biopharmaceutical companies test their drugs in 2D models and animal models. Precise 3D models provide a more physiologically relevant environment for drug testing because they mimic human reactions.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Early Stage Lung Cancer at Innovation Summit San Francisco Conference

Posted by fidest press agency su domenica, 17 novembre 2019

Navigation Sciences™ will provide an update at the annual Medtech Strategist Innovation Summit San Francisco 2019 Conference on its Image Guided, Video Assisted Surgery (iVATS™) technology for the minimally invasive identification and removal of early stage lung cancer, the company announced today. The conference will take place in Burlingame, California on November 19, 2019.
The emergence of CT chest scanning as an effective tool in high risk populations to detect lung cancer at an early stage and lower cancer deaths is creating new opportunities to improve lung surgery. Removal of small tumors deep inside the lung with appropriate margins remains a significant challenge, as insufficient distance between the tumor and resection margin is associated with recurrence and death. Current surgical approaches either remove excess tissue via lobectomy, which lowers recurrence risk but results in more impaired lung function, or smaller, wedge resections, which reduces lung impairment but may increase recurrence risk.The Navigation Sciences™ solution integrates with multi-modal (imaging and surgery) technology and includes an active, GPS enabled marker (fiducial), proprietary, real-time navigation algorithms, and tumor cutting devices that allow for surgical precision specific to the patient’s anatomy. Radiology images are synchronized with real-time information to enable the clinician to perform surgery with precision guidance. The technology’s proof-of-concept was demonstrated in a Phase I-II clinical trial published in the Journal of Surgical Oncology. In the study, involving 25 patients (23 with early stage lung cancer), there were no significant complications, all nodules were fully resected with negative margins, and the technology was shown to integrate with surgical workflow.There are an estimated 87,000 patients in the U.S. diagnosed each year with early stage lung cancer and that number is expected to grow with growing recognition of CT X-ray screening’s value in early detection and favorable reimbursement coverage. Beyond lung cancer, the technology has significant potential in other soft tissue cancer surgeries including breast cancer, where an estimated 250,000 lumpectomies are performed annually, as well as liver, thyroid and brain tumors.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

L’e-commerce nel Life Sciences

Posted by fidest press agency su giovedì, 14 novembre 2019

Milano Mercoledì 20 novembre 2019 17:30 – 19:00 Piazza Borromeo, 12. Il seminario si propone di discutere, con taglio pratico e operativo, delle peculiarità normative dell’e-commerce di farmaci, dispositivi medici e integratori alimentari. Si parlerà dei soggetti che lo possono effettuare e delle modalità e limiti con cui può essere svolto, soffermandosi sulle differenze tra i vari tipi di prodotti. Si prenderanno in considerazione alcuni modelli di business che si stanno diffondendo nella prassi (uso di app, consegna a domicilio, etc.) per evidenziarne gli aspetti più critici e fornire possibili soluzioni. La discussione sarà arricchita dalla presenza dell’avvocato tedesco Karolin Hiller dello studio legale McDermott Will & Emery, con pluriennale esperienza nel settore, che potrà allargare la prospettiva alla Germania, evidenziando le principali caratteristiche del quadro normativo tedesco in una ottica comparativa con l’ordinamento italiano. Il seminario si terrà interamente in lingua italiana.

Posted in Cronaca/News, Economia/Economy/finance/business/technology | Contrassegnato da tag: , , | Leave a Comment »

Bio-industry Events Promoting Innovation and Diversity in the Life Sciences

Posted by fidest press agency su giovedì, 13 giugno 2019

Tuesday, June 18th the organization will host a “BioMixer” at the Brewery Vivant, 925 Cherry St SE, Grand Rapids, MI 49506, from 5:00 – 7:00 p.m. The event will feature light food and craft brews and provide an opportunity to bio-industry professionals and enthusiasts to meet and mingle.
The following morning, Wednesday, June 19th, MichBio will host a “Women of MichBio” breakfast and discussion in partnership with Grand River Aseptic Manufacturing (GRAM) at Grand Valley State University – Seidman College of Business, 50 Front Ave SW, Grand Rapids, MI 49504 from 9:00 a.m. – 12:00 p.m. The event will feature a panel discussion with four senior employees at GRAM, all women, and will be moderated by Sok Kean Khoo, PhD of Grand Valley.
The panelists will discuss their differing paths to leadership at GRAM, the business implications of a culture committed to diversity and inclusion, and tips for other women and minorities looking to advance their career in an industry historical dominated by Caucasian males. Both events are open to all bio-industry participants including working professionals, students, faculty, and service providers in the medical device, pharmaceutical, agbio, and research sectors of the industry. They are free for MichBio members and $19 for nonmembers. Pre-registration is encouraged, but not required, at

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

The JMP Securities Life Sciences Conference

Posted by fidest press agency su giovedì, 6 giugno 2019

New York 20, 2019 10 a.m. ET Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the company will participate in the following conference in June:The JMP Securities Life Sciences Conference.
Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Genevant Sciences to Present at the Jefferies 2019 Healthcare Conference

Posted by fidest press agency su mercoledì, 5 giugno 2019

Genevant Sciences, a leading biopharmaceutical company focused on the discovery and development of RNA therapeutics utilizing multiple modalities, today announced that Bo Rode Hansen, MBA, PhD, President and Chief Executive Officer, is scheduled to present at the Jefferies 2019 Healthcare Conference in New York City on Friday, June 7, 2019 at 8:00 am EDT.Genevant leverages best-in-class RNA therapeutic delivery capabilities to develop a diverse pipeline of innovative product candidates designed to improve lives. While others are focused singularly on a particular RNA modality, Genevant’s lipid nanoparticle (LNP) technology, which enabled the first RNAi product approval, and ligand conjugate technology provide the potential to exploit multiple modalities, including mRNA, RNAi and gene editing, and to select the optimal one on a target-by-target basis. Genevant’s pipeline programs include both rare diseases with well established, monogenic causes and unique therapeutic approaches to more complex, large market diseases. Genevant is committed to transforming the future of human health.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Biocom Institute Awarded Grant to Support Veterans’ Careers in the Life Sciences

Posted by fidest press agency su mercoledì, 15 Maggio 2019

Biocom Institute, the non-profit workforce development and science, technology, engineering and math (STEM) arm of Biocom, today announced that it has received a $150,000 Workforce Accelerator Fund grant from the California Workforce Development Board to help introduce veterans to careers in the life sciences.The grant will help to support Biocom Institute’s “Gateway to Life Science Careers for Veterans” project, a mission that will accelerate the recognition of veterans’ existing skills and provide educational opportunities and networking with leaders from the life science industry. This includes creating the Veterans in Life Science Virtual Network (VLSVN), a resource aimed at improving job matching and assessment strategies to accelerate employment, as well as hosting a number of career symposiums and fairs, workshops and mentorship programs.“By providing a comprehensive set of resources for veterans looking to enter the industry, this grant will ultimately support the talent crisis our rapidly accelerating life science landscape is currently facing,” said Joe Panetta, CEO of Biocom. “Given the crossover of skillsets between veterans and the life science workforce, such as communication, leadership and mission-driven values, this group of individuals will synergistically support our industry in a broad range of ways.”

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Surefire Medical to Change Name to TriSalus Life Sciences

Posted by fidest press agency su venerdì, 14 settembre 2018

Surefire Medical, Inc. (Surefire) announced today the company is changing its name to TriSalus Life Sciences to better reflect the company’s contribution to patient care. TriSalus is focused on developing drug delivery technology for use in solid tumors and improving the administration of immuno-oncology (IO) therapies.“The re-naming of our company to TriSalus Life Sciences reflects an important step in our journey to build a leading oncology drug delivery company,” said TriSalus CEO Mary Szela. “As researchers identify more ways to fight cancer, successful outcomes for patients are increasingly being defined by three strategic pillars for oncology treatment: the administration of the right therapeutic, the stimulation of the immune system, and equally important: a targeted delivery system to augment the therapeutic index.” TriSalus derives from the Roman goddess Salus, who represents health, prosperity, safety and welfare, while tri, represents the three strategic pillars of integrated cancer treatment. “The new name inspires our organization to make a meaningful difference for patients undergoing cancer treatment,” added Szela.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Sickle Cell Disease Association of America, Inc. Partners With Emmaus Life Sciences, Inc.

Posted by fidest press agency su venerdì, 22 giugno 2018

The Sickle Cell Disease Association of America, Inc. (SCDAA) and Emmaus Life Sciences, Inc. have announced a new partnership involving national awareness and patient education initiatives to address the complications of sickle cell disease (SCD).Emmaus will provide unrestricted funding to provide educational materials for individuals living with SCD and their families to ensure that patients better understand the disease, treatment options and the importance of having comprehensive, coordinated medical care. The partnership also enhances national awareness efforts that will increase the dissemination of information to a broad audience through online platforms. Additionally, the partnership will help to strengthen SCDAA’s community-based member organizations by providing online tools to build capacity and better serve the sickle cell community. SCDAA’s member organizations ensure families have educational resources to gain knowledge of the disease, provide needed support services, host summer camps, support research and advocate on behalf of families for adequate treatment.
Sickle cell disease is a global health problem affecting millions of people around the world every day. It is estimated that approximately 100,000 Americans have SCD, and about 3,000,000 Americans have sickle cell trait. Each year, about 1,000 babies in the United States are born with SCD, and there is no universal cure for this life-threatening disease. After many years of clinical research and development, Emmaus Medical received FDA approval for Endari™ (L-glutamine oral powder) for patients living with sickle cell disease. Endari is the first treatment in nearly 20 years to reduce the acute complications of sickle cell disease in adults, and was the first treatment approved for use in children five years and older.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Alpine Immune Sciences to Present at Cowen 38th Annual Health Care Conference

Posted by fidest press agency su venerdì, 2 marzo 2018

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced the company will present at the Cowen 38th Annual Health Care Conference in Boston on Monday, March 12, 2018 at 4:10 pm Eastern Time.A live webcast of the presentation will be available online in the investor relations section of the company’s website at A replay of the presentation will be available on the company website for 90 days following the webcast.
Alpine Immune Sciences, Inc. is focused on developing novel protein-based immunotherapies using its proprietary variant Ig Domain (vIgD) platform technology. The vIgD platform is designed to interact with multiple targets including many present in the immune synapse. Alpine’s vIgDs are developed using a process known as directed evolution, which produces proteins capable of either enhancing or diminishing an immune response and thereby may potentially apply therapeutically to cancer, autoimmune, and inflammatory diseases. Alpine has also developed Transmembrane Immunomodulatory Protein (TIP) technology, based on the vIgD platform, to potentially enhance engineered cellular therapies.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Is Islam compatible with a secular Europe?

Posted by fidest press agency su mercoledì, 24 luglio 2013

Does the integration of Islam in Europe presuppose a prior ‘religious reformation’ that would make Islam compatible with so-called ‘European values’? And what are these European values? Are they Christian values or secular values? While all European constitutions and treaties stress the commitment towards ‘human rights’, ‘religious freedom’ and ‘democracy’, the status of ‘secularism’ is more complex.In this thought-provoking article, Olivier Roy introduces the concept of the ‘theological predicament’: the perceived connection between ‘Muslim values’ and the religion’s theological core. It’s the compatibility (or not) of these ‘values’ that are often called into question; to be fully integrated into European society, some maintain, Muslims must either have a liberal understanding of their religion to generate values in line with ‘European’ ones, or their theology must be reformed to allow the same.
At the heart of this ‘predicament’ is the mistaken belief that Islam is a single, universal set of values followed by all believers, and that there is no distinction between religion, culture and politics. This creates the impression of a single set of Muslim ‘values’ which are often perceived to be at odds with ‘Christian’, ‘secular’ or ‘European’ values.
But as Roy notes, it is difficult to speak of ‘Christian’ values in an age of declining church attendance, ‘Christian’ values that might not be shared by all Christians, and ‘secular values’ (especially on matters of family or sexuality) that clash with Christian ones. Indeed, the very notion of European ‘secularism’ itself is up for discussion in this article.Roy sees the current debate as not just about Islam, rather it is a continuation of the centuries-old European debate on the role of religion in politics and society. Our current focus on the theological content of Islam and on religious observance is, Roy notes; “a legacy of the European political culture and not of Islamic politics, culture or faith”.So, where does this leave Islam in Europe? Roy explores the different ways that European governments deal with the faith. In his view, current essentialist approaches to Islam challenge the established notion of the separation of church and state, and, paradoxically, the supposedly secular nature of the European state. Intervention, such as training ‘good’ imams, for example, runs against the secular value of religious freedom.In time, though, Roy believes that state interference will ‘format’ the religion, allowing it to adapt to its new environment. The gradual integration of Muslims into European society will also lead to new forms of religiosity and ‘theological updating’; the passing of generations will also see norms and values ‘recast in a European context’. Roy’s article also draws attention to Europe’s own identity crisis, noting that Islam ‘is the mirror through which Europe is looking’ at its own, confused, self. ‘Nostalgia is not a policy,’ Roy concludes hopefully, ‘the issue now is to set out what European values are, and no doubt most of the faithful will be able to share them.’
Taylor & Francis Group partners with researchers, scholarly societies, universities and libraries worldwide to bring knowledge to life. As one of the world’s leading publishers of scholarly journals, books, ebooks and reference works our content spans all areas of Humanities, Social Sciences, Behavioural Sciences, Science, and Technology and Medicine.
From our network of offices in Oxford, New York, Philadelphia, Boca Raton, Boston, Melbourne, Singapore, Beijing, Tokyo, Stockholm, New Delhi and Johannesburg, Taylor & Francis staff provide local expertise and support to our editors, societies and authors and tailored, efficient customer service to our library colleagues.

Posted in Estero/world news | Contrassegnato da tag: , , , | 1 Comment »

Dr. Jeffrey Davidson as Senior Director, Clinical Statistics

Posted by fidest press agency su sabato, 1 agosto 2009

CEO & Chairman Jim Walker  of Octagon Research Solutions, Inc., a pioneer and leading provider of breakthrough software and services to the life sciences industry, today announced the appointment of Jeffrey Davidson, Ph.D. to the position of senior director, Clinical Statistics. In this new position, Dr. Davidson will oversee all statistical activities and staff, as well as provide strategic direction and leadership for all statistical functions.Dr. Davidson comes to Octagon with extensive experience in statistics and biometrics, totaling over 20 years in industry. Prior to joining Octagon, he worked as senior vice president, Statistical Consulting at a global Contract Research Organization (CRO).  There, Dr. Davidson developed and led the business unit responsible for providing statistical consultancy to clients in the life sciences industry. In his previous position at this company, he served as senior vice president, Biometrics, where he directed all Biometrics and Medical Writing.  During his career, Dr. Davidson also served as vice president, Global Biometrics at Shire Development, Inc.Dr. Davidson’s additionally led statistical efforts at Purdue Pharma, led Medical Affairs Statistics at Hoffmann La Roche, and held a leadership role at Knoll. He further served as Therapeutic Area Statistical Lead at WyethDr. Davidson received his undergraduate degrees in Psychology (B.A) and Rehabilitation Education (B.S.) from Penn State. His post-graduate degrees include Special Education (M.Ed.) from the College of New Jersey and METER (Measurements, Evaluations, and Techniques of Experimental Research) (Ph.D.) from the University of Pennsylvania.
About Octagon Research Solutions, Inc. Octagon is a pioneer and leading provider of breakthrough software and services to the life sciences industry. Octagon’s eCTD and CDISC solutions provide the people, process and technology required to optimize drug development from data collection to submission. Our regulatory, clinical, process and software offerings provide a unique combination of deep domain knowledge, cross-functional electronic submission expertise, a holistic process approach, and integrated solutions. Octagon is headquartered in Wayne, PA, with European headquarters in Harrow, UK. Octagon’s EDC Operations are located in Mountain View, CA. For more information please visit

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »